On June 12, 2023, Barclay’s PLC filed a report with the SEC, indicating that it had reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by nearly 48% during the fourth quarter of the previous year. According to the filing, the firm owned just over 30,000 shares of UTHR after selling off more than 28,000 shares during that period. The value of those remaining shares was estimated at $8.5 million.
United Therapeutics Corp has been a leader in biotechnology for many years and is dedicated to developing innovative treatments for chronic and life-threatening conditions that affect millions of patients worldwide. It currently offers several products such as Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.
The company’s most recent earnings results were announced last May 3rd. According to those financial reports, UTHR had a return on equity of almost 16%, with a net margin hovering around 36%. Its quarterly revenue rose approximately 10% compared to last year’s figures.
These statistics underscore UTHR’s solid financial position despite Barclay’s PLC divesting themselves from a significant share of the stock. However, this move does raise questions about Barclay’s perspective on the long-term potential of UTHR given its commitment to investing in top performing companies within various industries.
It’s essential to note that Barclay’s divestiture decision may not reflect how investors view United Therapeutics’ future growth potential positively or negatively.
Other key stakeholders have remained relatively bullish about United Therapeutics Corp and their work towards treating serious illnesses through advanced biotechnology solutions. Analysts are predicting that UTHR may post an EPS figure of up to $18.33 for this current fiscal year.
As we move further into the fiscal year and beyond, investors will be monitoring United Therapeutics’ continued progress as they develop innovative treatments that can improve patient outcomes and potentially transform the healthcare sector.
[bs_slider_forecast ticker=”UTHR”]
United Therapeutics Corp Sees Activity from Institutional Investors and Hedge Funds Amid Renewed Interest in Life-Saving Products
The biotechnology company, United Therapeutics Corp., has recently seen a flurry of activity from institutional investors and hedge funds in both buying and selling their stock. Envestnet Asset Management Inc. saw their holdings in the company rise by 16.6% during the fourth quarter, with Belpointe Asset Management LLC increasing its position to approximately $82,000 during the same period. JPMorgan Chase & Co. also expanded its holding in United Therapeutics Corp., witnessing growth of 1.3% in its position, whereas State of New Jersey Common Pension Fund D additionally increased its position by 2.1% throughout Q4 2022.
Strategic Investment Advisors MI purchased a new position at around $293,000 for United Therapeutics Corp shares sometime within the fourth quarter alone. Shockingly high figures like this can be seen all around the company’s recent transactions involving institutional investors and hedge funds.
These changes are due to the renewed interest in the company’s products which cater to patients suffering from chronic or life-threatening conditions such as Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.
The growing attention on investing in United Therapeutics Inc.’s product lines is further solidified by positive remarks given by investment research firms such as JPMorgan Chase & Co., LADENBURG THALM/SH SH who valued UTHR at $256 per share back on May 4th only to then have their target price surpassed by Morgan Stanley who lowered it from $320 to $316 per share whilst giving UTHR an “overweight” rating at large.
HC Wainwright offered their own stance about investing in United Therapeutics mentioning its sound sell quality with lowered price objectives of approximately $300 at present whilst Strong Buy ratings were posted by StockNews.com on May 18th.
United Therapeutics’ CEO Martine A.Rothblatt and EVP Paul A.Mahon have both made sales of their holdings by selling 8,000 shares and 6,000 shares respectively between March 16th and March 17th this year. These sales were followed by numerous other insider sells totalling up to around $38 million over the last three months.
United Therapeutics remains a popular investment prospect for long term investors looking to engage in a profitable sector that caters to large scale patient needs for chronic illnesses. As a company with a market cap of $10.53 billion UTHR has the potential for an increase in stock value, which is especially appealing in its expanding industry sector including life sciences, biotech, and pharmaceuticals; all of which are continuously improving technological innovations that deliver patient-centric outcomes as top priorities.